OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Urology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Sexual recovery interventions following prostate cancer treatment	187
Novel intravesical gemcitabine delivery system (TAR-200) for neoadjuvant treatment of MIBC: context is everything	170
Texture analysis for patient selection	150
Single-cell and spatial sequencing of kidney cancer	120
Human-relevant urothelial model provides insight into infection strategies and host response	102
Krause corpuscles act as genital vibration detectors	81
Immune infiltration associated with outcomes	71
Semen quality recovery following COVID-19	68
PARP inhibitors plus enzalutamide to treat mCRPC	67
Urine microbiota differ in bladder cancer	66
Top, bottom or vers? Creating a more equitable health system for sexual and gender minority patients with prostate cancer	66
Micro-ultrasound for prostate cancer	65
Advancing the state of the art in congenital obstructive uropathy	64
Considering urology in a planetary context	62
Implementation of patient-reported outcome measures into health care for men with localized prostate cancer	59
Preclinical models of bladder cancer: BBN and beyond	58
Time for women-centred gynaecology	58
A clinical guide to rare male sexual disorders	58
High-dose chemotherapy for relapsed testicular germ cell tumours	55
Proteomic-based analysis of testicular interstitial fluid	52
A new text message-based platform for self-management of patients with IC/BPS	50
Prevalence of gender dysphoria in Japan	50
FOXA2–KIT-driven lineage plasticity in NEPC	50
Overcoming antibiotic resistance in complicated UTI	46
Is SARS-CoV-2-induced testicular damage in hamsters relevant?	43

Evolution of the World Health Organization semen analysis manual: where are we?	42
Madrid plays host to a celebration of urology	42
Promise without practice — charting the path forward for bladder cancer biomarkers	42
What happens in Vegas … shapes the future of urology	40
Hallmark discoveries in the biology of non-Wilms tumour childhood kidney cancers	40
Microfluidic sperm selection	40
Galectins as potential therapeutic targets in STIs in the female genital tract	39
Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer	39
Metaverse in surgery — origins and future potential	39
The evolving landscape of monogenic nephrolithiasis and therapeutic innovations	39
Antibiotic therapy for treating overactive bladder is not supported by clinical evidence	39
Pembrolizumab + axitinib beyond first-line therapy for mRCC	38
COVID can’t kill CopMich collaboration	37
A non-invasive assay for UTUC diagnosis	37
Vaccination to prevent untreatable gonorrhoea	36
Resolving the puzzle of same-sex sexual interactions	36
Bioinformatics in urology — molecular characterization of pathophysiology and response to treatment	34
The mechanism of action of neuromodulation in the treatment of overactive bladder	33
Quest for a genetic biomarker for sickle cell disease priapism: rationale, progress and implications	33
PEACEing together prostate cancer therapy	33
Efficacy of the Revi system in treating urgency urinary incontinence	33
Persistent Müllerian duct syndrome — a rare but important cause of male factor infertility	32
EMUC25: shaping tomorrow’s uro-oncology care	32
Personalized 3D models for prostate cancer surgery	32
Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway	32
Measuring and improving the cradle-to-grave environmental performance of urological procedures	30
Pain management in percutaneous nephrolithotomy — an approach rooted in pathophysiology	30
Sexual orientation, gender identity and COVID: a complicated picture	28
Secondary kidney stones — remove or leave?	27
Effect of high glucose on E. coli	27
The magic of MagSToNE	27
Author Correction: Can PROMs improve racial equity in outcomes after prostatectomy?	27
Cribriform morphology affects mpMRI imaging	27
Rucaparib improves PFS in patients with BRCA1/2-altered mCRPC	27
A distinct TAM subset mediates immunotherapy resistance in prostate cancer	25
Women in urology: the past	25
Promising efficacy of UTI vaccines as an alternative to antibiotics	24
AUA returns to its former glory in Chicago	24
Excluding PLND in favourable intermediate-risk prostate cancer: a PSMA-PET-directed perspective	24
Successful mentorship for women in urology — a new era	24
Prostate cancer in transgender women — challenges in research and clinical care	24
Robots learning to imitate surgeons — challenges and possibilities	23
Is it time to rethink the current patient-reported outcome measures?	22
Microultrasonography-guided prostate cancer biopsy	21
Centralization of care for rare genetic syndromes associated with cancer: improving outcomes and advancing research on VHL disease	20
Videourodynamics — role, benefits and optimal practice	19
Technical modifications to improve erectile function recovery after radical prostatectomy	19
Sexual health and treatment-related sexual dysfunction in sexual and gender minorities with prostate cancer	19
Current and emerging strategies to curb antibiotic-resistant urinary tract infections	18
Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards	18

A clinical overview of people living with HIV and genitourinary cancer care	18
Androgen receptor pathway inhibitor combination in prostate cancer	17
Going in circles: circMGA–HNRNPL feedback loop in bladder cancer	17
Management and cost of stent encrustation in pregnancy	16
Detecting lymph node metastases for personalized radiotherapy in patients with prostate cancer	16
De-clear cell differentiated renal cell carcinoma — a new therapeutic target	15
Turning up the heat: CTLA4 blockade in urothelial cancer	15
AI for antibiotic design	15
Immune-based therapies in penile cancer	15
Pride, not prejudice	15
The evolving treatment landscape of metastatic urothelial cancer	14
The future of patient-derived xenografts in prostate cancer research	14
Evolving language reflects evolving understanding: updated terms for anatomical description in i/VSC/DSD	13
The prognostic role of stroma in UTUC	13
Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective	13
Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning	13
Uncovering a link between COVID-19 and renal cell carcinoma	12
Turning back time in the testes	12
We all get erections — de-gendering sexual arousal dysfunction in the ICD	12
Hallmark discoveries in the biology of Wilms tumour	12
The value of women urologists — individual and institutional imperatives to address salary equity	12
The unclear role of PET–CT in localized radiorecurrent prostate cancer	12
Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer	11
Pelvic-fascia-sparing techniques and outcomes with RARP	11
Current and future pharmacotherapy for female sexual dysfunction	11
Och AI the noo from SIU	11
New evidence and novel techniques for assessing intraoperative margins during radical prostatectomy	11
Breaking the silence: normalizing receptive anal intercourse for patients, for people and for myself	11
The shifting treatment paradigm of metastatic renal cell carcinoma	11
Effects of COVID-19 vaccine on semen parameters	10
Men hold the balance of power	10
Vitamins as regulators of calcium-containing kidney stones — new perspectives on the role of the gut microbiome	10
CMA mediates resistance to androgen inhibitors in prostate cancer	10
Improved phenotypic classification of male infertility to promote discovery of genetic causes	10
BAUSing back in Birmingham	10
Power up to investigate PrEP	10
ARNEO: neoadjuvant degarelix + apalutamide before surgery for high-risk prostate cancer	9
Diagnosis of ccRCC	9
Tuft cells in prostate cancer	9
Patient selection is key in IMbassador250	9
Metabolism, mitochondria and metastasis in kidney cancer	9
Semen parameters across testicular cancer stages	8
Mechanisms of the intestinal and urinary microbiome in kidney stone disease	8
Male infertility and somatic health — insights into lipid damage as a mechanistic link	8
The ins and outs of penile erection	8
A prompt-based stewardship to reduce extended-spectrum antibiotic treatment in UTI	8
Microbiota manipulation to prevent oxalate kidney stone formation	8
Mellow yellow: BilR reduces bilirubin to urobilinogen	8
MRI diagnosis and radical prostatectomy outcomes	8
Spatiotemporal trends in human semen quality	8
Author Correction: Atypical intraductal proliferation in prostate biopsy — a diagnostic grey zone with clinical implications	8
Toilet-based continuous health monitoring using urine	7
Prostate luminal progenitor cells: from mouse to human, from health to disease	7
Syphilis on the rise — a need for alternative therapies and vaccines	7
Pronouns in English: a user’s guide	7
Stepping up to prevent bacterial vaginosis recurrence	7
Testosterone replacement therapy and spermatogenesis in reproductive age men	7
Sperm activity affected by endometriosis	7
Advances in sliding clip renorrhaphy for partial nephrectomy	7
Pathophysiology and potential multimodal therapeutic strategies for IC/BPS	7
Particulate matter leaves a bitter taste in testes	7
Chlorination by-products in drinking water — association with bladder cancer risk	7
Von Hippel–Lindau protein signalling in clear cell renal cell carcinoma	6
Artificial intelligence in the management of prostate cancer	6
The effects of diet on prostate cancer outcomes	6
Urology on a changing planet: links between climate change and urological disease	6
A great gathering at the 4th Clinical and Scientific Advances in UTI conference	6
Influence of substance use on male reproductive health and offspring outcomes	6
Clinical trial design for non-muscle-invasive bladder cancer	6
The future of pelvic lymph node dissection for urological malignancies	6
Visual clues — dermatological manifestations of sexually transmitted infections in men	6
Genetic and biological drivers of prostate cancer disparities in Black men	6
Feasibility and potential of an MRI-based prostate cancer screening	6
ADT intensification to treat biochemically recurrent prostate cancer	6